QualityStocks would like to highlight Bioanalytical Systems, Inc.(NASDAQ: BASI). The company provides contract research services and niche instrumentation, serving the life sciences industries, primarily in drug research and development. The company's objective is to be the leading provider of professional, technical, and scientific resources to the drug discovery industry.
In the company’s news yesterday,
Bioanalytical Systems recently announced a collaboration with Data Sciences International (DSI) to conduct a pioneering study that combines Bioanalytical Systems’ Culex-L automated sampling system with PhysioTel Digital, DSI’s latest large animal telemetry technology. DSI is a biomedical research company with its focus on preclinical systems physiology and pharmacology.
In this groundbreaking study, BASi’s Culex-L automated in vivo sampling system will simultaneously gather biological samples at pre-programmed intervals while DSI telemetry devices collect heart rate, blood pressure, and other cardiovascular data. The gathering of these various types of data formerly required two separate experiments and allowed only discontinuous data collection.
Combining Culex with telemetry will result in reductions in cost, number of test subjects, and subject test levels for the automated blood sampling and telemetry (ABST) system, as well delivery of better data. This will collectively lead to better decision making. The study will lay the groundwork for additional safety pharmacology studies to further complement BASi’s CRO services expertise.
These efforts are in response to customer requests for additional and improved pharmacokinetic data, which is crucial for early decision-making in the drug discovery process. Joining DSI’s telemetry with BASi’s automation is a natural fit.
Bioanalytical Systems is a pharmaceutical development company engaged in providing contract research services and monitoring instruments to the world’s premier drug development companies and medical research organizations. The company is focused on the development of innovative services and products that enhance efficiency and decrease the cost of taking a new drug to market.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
